SmiLe Incubator and PULS have signed an agreement that provides SmiLe incubator companies with access to about 40 people from the research community and the medical device and pharmaceutical industries that are associated with PULS.
PULS invests in and develops early-phase life science companies and has partnered with experienced entrepreneurs, researchers and industry people from the Swedish pharmaceutical and medical device industries.
With the new agreement, the incubator companies in SmiLe Incubator will have access to an even broader skills platform than today because PULS partners will be available to provide advice. The agreement will become effective in June.
Once the new agreement comes into effect, PULS representatives will be available on a regular basis at SmiLe in Lund.
“This collaboration provides a fabulous opportunity for us to offer unique knowledge to the companies. In addition, companies can get advice when necessary from experienced individuals who provide an external perspective. Our ambition is to build a large ‘advisory board’ around SmiLe and the agreement with PULS is a first and extremely important building block in this initiative,” says Ebba Fåhraeus, CEO of SmiLe Incubator.
“Through our local presence in Lund we create a meeting place that gives us access to exciting new early projects. At SmiLe we benefit from our natural proximity to the life science cluster in Lund, including academic research at Lund University. We are only too pleased if we can then, in turn, contribute experience from our business and help to create new constellations,” says Sarah Fredriksson, CEO of PULS.
About PULS Invest:
P.U.L.S. AB (Partners for Development Investments in Life Sciences) is a Swedish life science company with a unique combination of researchers and industrialists who, together with innovators, commercialize ideas through capital, know-how and committed partnership. PULS invests in early projects and actively develops them in close collaboration with the innovators, all the way from idea to projects attractive to the industry. Since 2002, PULS has launched eleven project companies, divested two, licensed one and listed two (AcuCort and LIDDS). PULS is headquartered in Helsingborg. Current PULS projects include: Adenovir Pharma, Belina, Glactone Pharma, Laccure, Oncorena och Trophea. www.pulsinvest.se.
For additional information, please contact:
Ebba Fåhraeus, CEO at SmiLe Incubator
Mobile: +46 734000433
Or visit our mediaroom
SmiLe is a business incubator based in Medicon Village in Lund. SmiLe helps entrepreneurs and startup companies to develop and commercialize new ideas. Our main task is to help the management teams of these companies to navigate the complexities of business development, financing, recruitment and risk management. There are currently around 20 companies in SmiLe, which together have attracted more than SEK 1 000 million in venture capital to date since 2014. Approximately 100 people, representing 20 nationalities, and almost 50 percent of whom are women, work at SmiLe incubator. SmiLe is a community consisting of experts, business advisors, incubator companies as well as alumni companies, which when combined provide a unique opportunity for Life Science Industry startups to benefit from their extensive collective experience. The opportunity also includes an infrastructure that is unique of its kind in Sweden, with well-equipped laboratories and advanced instrumentation. SmiLe has its major financing from Lunds university, Lund Municipality, Region Skåne och Medicon Village.